FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

HIKAL Consensus Forecast

No. of reports in last year
3
No. of analysts
2
Average Consensus Forecast
171.33
Consensus Potential
25.46%

HIKAL Price Target Potential

BrokerageTargetPotential
Sushil Finance18431.88%
ICICIdirect.com14010.46%

HIKAL Targets in FrontPage Forums

0 Users have submitted 0 trade ideas of Rs. 0 for HIKAL
0% Bullish
0% Bearish
See buy or sell ideas on FrontPage Forums >>

HIKAL Ratings

Long term HIKAL rating by FrontPage users
5/5 (2 Ratings)

3 HIKAL share price target reports by brokerages below. See what is analyst's view on HIKAL share price forecast, rating, estimates, valuation and prediction behind the target. You may use these research report forecasts for long-term to medium term for your investment or trades in 2020.
  1. Home
  2. HIKAL Forum
  3. HIKAL Price Target

HIKAL Share Price Target

HIKAL Share Price Target - Broker Reports - 2020

23-Jun-20
Price @ Call: 127.96
Target: 184
BUY

HIKAL Share Price Target - Broker Reports - 2019

30-Oct-19
Price @ Call: 117.09
Target: 140
BUY
The hitherto unblemished growth track record was impacted by certain unforeseen one-offs (flood and water cut) besides a scheduled shutdown for capacity expansion. While the management has assured on substantial recouping (if not entire) of the lost business in Q3, Q4, the lack of disclosures of these events has already taken a toll on the stock price. Coming back to earnings, the full year revenue guidance of 5-10% seems difficult. However, going by the capex guidance, things are looking promising for FY21. On the margins front, gross margins are improving due to focus on high margin products. However, the management has to improve on the disclosure front as this is one of the major sources of information for B2B players like Hikal. But for this lacuna, Hikal continues to offer a compelling value proposition as it continues to expand in both pharma and crop protection segments with separate focus and a calibrated approach. This bodes well in the current scenario when Chinese supply disturbances are likely to create opportunities for Indian players both in APIs and crop protection CDMO. We arrive at a valuation of rs 140 based on 14x FY21E EPS of Rs 11.7.
... Read more
2-Aug-19
Price @ Call: 146.8
Target: 190
BUY
Key takeaways from Q1 numbers were strong growth in crop protection, steady growth in pharma but lower blended level margins that are attributable to a product mix and plant related expenses. The management still remains conservative on the revenue growth guidance front (10-15% in FY20 maintained) as the focus is likely to be on high margin products besides a close watch on capacities. With proven capabilities and management pedigree, we believe Hikal offers a compelling value proposition as it continues to expand in both pharma and crop protection segments with separate focus and a calibrated approach. This bodes well in the current scenario when Chinese supply disturbances are likely to create opportunities for Indian players both in APIs and crop protection CDMO. We arrive at a valuation of Rs 190 based on 14x FY21E EPS of | 13.6.
... Read more
13-May-19
Price @ Call: 174.7
Target: 205
BUY
For years, the company has been dealing with high profile MNCs like Merck & Co, Bayer, Syngenta, BASF, Pfizer to name a few. With proven capabilities and management pedigree, we believe Hikal offers a compelling value proposition as it continues to expand in both pharma and crop protection segments with separate focus and a calibrated approach. This bodes well in the current scenario when Chinese supply disturbances are likely to create opportunities for Indian players both in APIs and crop protection CDMO. The company has spent ~| 500 crore over the last five years to augment capacities. After years of volatility in growth, Hikal has been witnessing a relatively stable growth trajectory. We arrive at a valuation of Rs 205 based on 15x FY21E EPS of Rs 13.7.
... Read more
18-Apr-19
Price @ Call: 177.91
Target: 218
BUY
4-Mar-19
Price @ Call: 167.01
Target: 200
BUY
For years, the company has been dealing with high profile MNCs like Merck & Co, Bayer, Syngenta, BASF, Pfizer to name a few. With proven capabilities and management pedigree, we believe Hikal offers a compelling value proposition as it continues to expand in both pharma and crop protection segments with separate focus and a calibrated approach. This bodes well in the current scenario when Chinese supply disturbances are likely to create opportunities for Indian players both in APIs and crop protection CDMO. The company has spent ~| 500 crore over the last five years to augment capacities. After years of volatility in growth, Hikal has been witnessing a relatively stable growth trajectory. We expect sales, EBITDA, PAT to grow at a CAGR of 15%, 18%, 30%, respectively, in FY19-21E on the back of new launches and better operating leverage. Simultaneously, we also expect a 330 bps RoCE improvement to 17.3% through FY21. We arrive at a valuation of Rs 200 based on 15x FY21E EPS of Rs 13.3.
... Read more

HIKAL Share Price Target - Broker Reports - 2018

12-Oct-18
Price @ Call: 160.62
Target: 190
BUY

HIKAL Share Price Target - Broker Reports - 2017

28-Apr-17
Price @ Call: 141.33
Target: 193.33
BUY
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • HIKAL Share Price Target Today- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 3131.5
    Upside Target 2130.15
    Upside Target 1128.1
    Pivot126.75
    Downside Target 1124.7
    Downside Target 2123.35
    Downside Target 3121.3
  • HIKAL Share Price Target weekly- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 3151.3
    Upside Target 2143.15
    Upside Target 1135.4
    Pivot127.25
    Downside Target 1119.5
    Downside Target 2111.35
    Downside Target 3103.6
  • HIKAL Share Price Target monthly- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 3160.43
    Upside Target 2147.72
    Upside Target 1136.43
    Pivot123.72
    Downside Target 1112.43
    Downside Target 299.72
    Downside Target 388.43
  • HIKAL Share Price Target today- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 3130.15
    Upside Target 2128.85
    Upside Target 1128.05
    Pivot126.75
    Downside Target 1125.45
    Downside Target 2124.65
    Downside Target 3123.35
  • HIKAL Share Price Target weekly- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 3143.15
    Upside Target 2137.08
    Upside Target 1133.32
    Pivot127.25
    Downside Target 1121.18
    Downside Target 2117.42
    Downside Target 3111.35
  • HIKAL Share Price Target monthly- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 3147.72
    Upside Target 2138.55
    Upside Target 1132.88
    Pivot123.72
    Downside Target 1114.55
    Downside Target 2108.88
    Downside Target 399.72
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.
PrivacyTerms
FrontPage © 2020